Takeda
Tempus, Takeda Expand Collaboration to Use Multimodal Data for Oncology R&D
Takeda will use Tempus' multimodal datasets and biological modeling capabilities in its cancer therapeutic development work.
BostonGene, Takeda Form Immunotherapy Clinical Research Partnership
The firms will apply BostonGene's AI-driven multiomics platform to identify molecular drivers of cancer and predictive markers of treatment response.
FoundationOne Liquid Biopsy Assay Gets FDA OK as Companion Diagnostic for Takeda's Exkivity
Foundation Medicine said its assay is the only blood-based comprehensive genomic profiling platform to have gained this approval for Takeda's EGFR drug.
Adaptive Biotechnologies, Takeda Partner to Develop Treatments for Lymphoid Malignancies
The multiyear collaboration will use Adaptive's ClonoSeq assay to measure minimal residual disease status as an endpoint for Takeda’s clinical trials.
The CDPath prognostic tool gives Crohn's patients risk scores for serious complications within three years, so they can make more informed treatment decisions.
Aug 15, 2019
Apr 16, 2014